Notes in Ovarian cancer

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	FRS \| Ovary \| 1.1 \| Anatomy
Published	02/18/2024	FRS \| Ovary \| 1.2 \| Epidemiology (general)
Published	02/18/2024	FRS \| Ovary \| 1.3 \| Risk factors (general)
Published	02/18/2024	FRS \| Ovary \| 1.4 \| Biologic behaviour (general)
Published	02/18/2024	FRS \| Ovary \| 2.1 \| Clinical presentation
Published	02/18/2024	FRS \| Ovary \| 2.2 \| Workup
Published	02/18/2024	FRS \| Ovary \| 2.3.1 \| CA 125 \| Discuss the role of CA 125 in the setting of ovarian cancer
Published	02/18/2024	FRS \| Ovary \| 1.5 \| Pathologic classification \| List the WHO classification for ovarian neoplasms
Published	02/18/2024	FRS \| Ovary \| 1.6.1 \| Epithelial \| General
Published	02/18/2024	FRS \| Ovary \| 1.6.2.1 \| Epithelial \| Benign \| Cystadenoma
Published	02/18/2024	FRS \| Ovary \| 1.6.3 \| Epithelial \| High grade serous
Published	02/18/2024	FRS \| Ovary \| 1.6.4 \| Epithelial \| Low grade serous
Published	02/18/2024	FRS \| Ovary \| 1.6.5 \| Epithelial \| Mucinous
Published	02/18/2024	FRS \| Ovary \| 1.6.6 \| Epithelial \| Endometrioid
Published	02/18/2024	FRS \| Ovary \| 1.6.7 \| Epithelial \| Clear cell
Published	02/18/2024	FRS \| Ovary \| 1.6.8 \| Epithelial \| Transitional cell carcinoma (Brenner tumour)
Published	02/18/2024	FRS \| Ovary \| 1.7.1 \| GCT \| General
Published	02/18/2024	FRS \| Ovary \| 1.6.2.2 \| Epithelial \| Benign \| Cystadenofibroma
Published	02/18/2024	FRS \| Ovary \| 1.7.2 \| GCT \| Embryonal \| Dysgerminoma
Published	02/18/2024	FRS \| Ovary \| 1.7.3 \| GCT \| Embryonal \| Yolk-sac tumour
Published	02/18/2024	FRS \| Ovary \| 1.7.4 \| GCT \| Embryonal \| Choriocarcinoma
Published	02/18/2024	FRS \| Ovary \| 1.7.5 \| GCT \| Embryonal \| Embryonal carcinoma
Published	02/18/2024	FRS \| Ovary \| 1.7.6 \| GCT \| Embryonal \| Immature teratoma
Published	02/18/2024	FRS \| Ovary \| 1.7.7 \| GCT \| Mature \| Mature teratoma
Published	02/18/2024	FRS \| Ovary \| 1.8.1 \| Sex cord stromal \| General
Published	02/18/2024	FRS \| Ovary \| 1.8.2 \| Sex cord stromal \| Granulosa-theca cell tumours
Published	02/18/2024	FRS \| Ovary \| 1.8.3 \| Sex cord stromal \| Sertoli-Leydig cell tumours
Published	02/18/2024	FRS \| Ovary \| 1.8.2 \| Sex cord stromal \| Fibromas, thecomas and fibrothecomas
Published	02/18/2024	FRS \| Ovary \| 2.4 \| Differential diagnosis ovarian mass
Published	02/18/2024	FRS \| Ovary \| 1.9.1 \| Premalignant lesions of the fallopian tube (STIL, STIL-US, STIC)
Published	02/18/2024	FRS \| Ovary \| 1.9.1 \| Metastases to ovaries and Krukenberg tumours
Published	02/18/2024	FRS \| Ovary \| 2.3.2 \| OVA 1
Published	02/18/2024	FRS \| Ovary \| 2.5 \| Pathology report
Published	02/18/2024	FRS \| Ovary \| 2.6.2 \| Prognosis by stage / histology
Published	02/18/2024	FRS \| Ovary \| 2.6.1 \| Staging
Published	02/18/2024	FRS \| Ovary \| 1.9.3 \| Prognostic factors
Published	02/18/2024	FRS \| Ovary \| 3.1 \| Screening and prevention \| General
Published	02/18/2024	FRS \| Ovary \| 3.2 \| Screening and prevention \| Management of asymptomatic BRCA1/2 mutation carriers
Published	02/18/2024	FRS \| Ovary \| 3.3 \| Genetics associated with ovarian cancer
Published	02/18/2024	FRS \| Ovary \| 3.4 \| BRCA testing \| Discuss who to offer BRCA testing to and the pros/cons
Published	02/18/2024	FRS \| Ovary \| 4 \| Management \| Overview
Published	02/18/2024	FRS \| Ovary \| 5.1 \| Epithelial \| Surgery \| Role and procedure
Published	02/18/2024	FRS \| Ovary \| 5.2.1 \| Epithelial \| Neoadjuvant chemotherapy (controversial)
Published	02/18/2024	FRS \| Ovary \| 5.2.2.1 \| Epithelial \| Adjuvant chemotherapy \| Early stage low risk
Published	02/18/2024	FRS \| Ovary \| 5.2.2.2 \| Epithelial \| Adjuvant chemotherapy \| Early stage high risk
Published	02/18/2024	FRS \| Ovary \| 5.2.2.3 \| Epithelial \| Adjuvant chemotherapy \| Advanced stage (III and IV)
Published	02/18/2024	FRS \| Ovary \| 5.2.3.1 \| Epithelial \| Maintenance therapy - BRCA1/2 positive
Published	02/18/2024	FRS \| Ovary \| 5.2.3.2 \| Epithelial \| Maintenance chemotherapy \| High risk (e.g. ascites, pleural effusion). BRCA negative
Published	02/18/2024	FRS \| Ovary \| 5.2.4 \| Epithelial \| Chemotherapy side effects
Published	02/18/2024	FRS \| Ovary \| 5.3.1 \| Epithelial \| Radiotherapy (WART) \| Rationale, indications, regime, guidline recommendations, toxicity
Published	02/18/2024	FRS \| Ovary \| 5.3.2 \| Epithelial \| Radiotherapy (WART) \| Evidence
Published	02/18/2024	FRS \| Ovary \| 5.5 \| Epithelial \| Recurrent disease \| Management
Published	02/18/2024	FRS \| Ovary \| 5.4 \| Epithelial \| Follow up
Published	02/18/2024	FRS \| Ovary \| 6 \| Germ cell tumours \| Management
Published	02/18/2024	FRS \| Ovary \| 7 \| Sex cord stromal tumours \| Management
Published	02/18/2024	FRS \| Ovary \| 8 \| RT technique \| Whole abdominal radiotherapy (WART)
Published	02/18/2024	FRS \| Ovary \| 5.6 \| Borderline epithelial tumours \| Management
Status	Last Update	Fields